Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06563388 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

Study acronym: ID-COMET
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv6
  2. Eligibility criteria expanded, about 19 wordsv5
  3. Primary and study completion dates: Oct 1, 2032 to Sep 18, 2032
    • Start date changed from estimate of Oct 1, 2024 to Sep 18, 2024
    v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v3
  5. Interventions: Radiation Therapy (Radiation) to Best Practice (Other), Stereotactic Ablative Radiotherapy (Procedure)
    • Secondary endpoints: details revised at 1 of 2 entries
    • Study title shortened, about 8 words
    • Study arms: 2 to 3
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancers
Trial Details
NCT Number NCT06563388
Lead Sponsor Roswell Park Cancer Institute
Conditions
(from sponsor)		 Oligometastasis, Lung Cancer, Colo-rectal Cancer, Prostate Cancer
Related terms Colonic Neoplasms, Lung Neoplasms, Prostatic Neoplasms
Enrollment 800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov